Pan-Asian Course for Training in MS And Neuroimmunology (PACTMAN), a webinar teaching series, was developed to support the education mission of PACTRIMS to the membership at large and other healthcare providers who have an interest and role in managing patients with neuroinflammatory diseases such as MS, neuromyelitis optica spectrum disorder (NMOSD), Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and other related disease.
PACTMAN was inaugurated in 2021 with 3 webinars. We taught clinical approaches using case vignettes, practical management strategies contextualised for resource-poor countries and theme-based topics. The target audience included neurologists, general internists, trainees, nurses and other healthcare professionals. Speakers were drawn from across the Asia Pacific region. A total of 386 participants (from 24 countries) attended the webinars.
In 2022, PACTMAN aims to build on this success with 4 webinars planned. We intend to broaden the scope and range of central nervous system (CNS) inflammatory conditions and topics. These would include practical aspects of immunopathophysiology, interpretation of diagnostic tests and holistic management of patients. All talks will be contextualized to be applied in resource-poor settings and will include discussion of the influence of the COVID pandemic. We welcome and encourage participation from colleagues in the Asia Pacific region and beyond
General neurologists, neurology trainees and healthcare professionals with interests in neurology/neuroimmunology in the Asia-Pacific region.
If you are interested in case-based learning with emphasis on practical clinical approach, then this is the course for you.
Dr Sudarshini Ramanathan is a neurologist and clinician-scientist, with subspecialty expertise in neuroimmunology. Dr Ramanathan is an NHMRC Investigator Fellow, and a staff specialist neurologist at Concord Hospital in Sydney, Australia, where she looks after patients with autoimmune neurological disorders. She is a Senior Research Fellow and heads the Translational Neuroimmunology Group at the University of Sydney, where she leads a clinical and fundamental science research program focused on understanding disease pathogenesis, and improving the diagnosis and treatment of autoimmune neurological disorders including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder, and autoimmune encephalitis. In 2013, Dr Ramanathan established and has since been the lead investigator of the Australian and New Zealand MOG Study Group. This collaborative platform now encompasses over 150 clinicians from 45 centres in Australasia and evaluates a cohort of over 500 children and adults with MOGAD.
1700 hours to 1745 hours
The immunopathogenesis of MS, NMOSD and MOGAD
Dr Sudarshini Ramanathan
Neurologist and clinician-scientist, with subspecialty expertise in neuroimmunology
Central nervous system demyelination due to inflammatory damage to myelin can result in blindness, paralysis, and significant neurological disability. While multiple sclerosis (MS) is the most prevalent cause of demyelination, important subgroups of patients with antibody-mediated demyelination have been identified, including neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disease (MOGAD). These disorders have now been established as distinct entities, with divergent underlying pathogenic mechanisms of action, clinical and radiological phenotypes, therapeutic responses, and outcomes. This talk will detail important factors identified in the immunopathogenesis of these disorders, including the interactions between non-modifiable risk factors such as age, gender, and ethnicity, as well as HLA risk profiles, infectious triggers, and environmental influences. This session will highlight what is known of pathogenic disease processes in central nervous system demyelination, and how our understanding of the underlying immunobiology can inform precision therapeutics.
1745 hours to 1830 hours
Prognostic factors in MS / NMOSD / MOGAD
Dr Jyh Yung Hor
Consultant Neurologist at the Department of Neurology, Penang General Hospital, Penang, Malaysia
There is differential prevalence of MS, NMOSD and possibly MOGAD in Asian countries when compared to the West. Early and accurate diagnosis of these diseases will be important for the appropriate treatment to be instituted. Several genetic and environmental risk factors have been identified for these diseases, and some of these factors may affect the prognosis and disease outcome. This talk focuses on the demographics (age, sex, race), clinical features and phenotypes, pregnancy, environmental factors (e.g., vitamin D, smoking), as well as certain biomarkers that may influence the prognosis of these neuroinflammatory diseases